Evaluation of prognostic factors for advanced ovarian cancer treatment with an emphasis on optimal primary cytoreduction

被引:0
作者
Vrhkar, Natasa [1 ]
Vakselj, Ales [1 ]
Verdenik, Ivan [1 ]
Smrkolj, Spela [1 ]
Barbic, Matija [1 ]
Cvjeticanin, Branko [1 ]
Meglic, Leon [1 ]
Kobal, Borut [1 ]
机构
[1] Univ Klin Ctr Ljubljana, Ginekol Klin, Klin Oddelek Ginekol, Ljubljana 1000, Slovenia
来源
ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL | 2012年 / 81卷 / 7-8期
关键词
ovarian cancer; prognostic factors; cytoreduction; residual tumour; GYNECOLOGIC-ONCOLOGY-GROUP; SURVIVAL; SURGERY; CARCINOMA; IMPACT;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Initial surgical debulking followed by a systemic chemotherapy is the standard treatment sequence for advanced ovarian cancer (AOC) treatment. The purpose of this article is to evaluate prognostic factors that impact the success of AOC treatment. Methods: All patients with AOC (FIGO stage III and IV) who were surgically treated at the Division of Gynaecology, University Medical Centre of Ljubljana, in the period from 2003 to 2008 and further received cytotoxic chemotherapy at the Institute of Oncology in Ljubljana were included in this retrospective study. Women with advanced borderline ovarian cancer and patients who initially received neoadjuvant chemotherapy and those whose adjuvant chemotherapy was not platinum-based were excluded from the analysis. Results: A total of 159 women were enrolled in the study, while data were analyzed for 116 patients. Their median age was 59 years (23-80 years) and did not have a significant influence on the treatment outcome. Clear-cell histological type of AOC was an important risk factor for a disease-free interval (DFI) (HR = 2.41, CI 95 % 0.9-5.9; p = 0.08) and overall survival (OS) (HR 4.045; 95.0% CI 1.5-10.6; p = 0.003). Post-operative residual tumour larger than 2 cm represented a statistically independent risk factor for poor OS. Residual tumour in the upper abdomen did not represent a statistically significant risk factor either for DFI (HR = 1.93; CI 95 % 0.9-4.06; p = 0.08) or for OS (HR = 1.47; 95.0 % CI 0.5-3.8; p = 0.491). Median follow up time was 29.5 months, median DFI 18 months (95 % CI 16-20) and median OS 32 months (95 % CI 22-42). 74 (63.8 %) patients died. Conclusion: Clear-cell histological type of AOC and residual tumour larger than 2 cm are the most important risk factors for early progress of the disease and poor OS. Hence improvement of surgical treatment is crucial for better treatment outcomes for patients with AOC. The latter can be achieved by an interdisciplinary surgical approach.
引用
收藏
页码:509 / 516
页数:8
相关论文
共 50 条
  • [31] Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Shih, K. K.
    Chi, D. S.
    Barakat, R. R.
    Leitao, M. M., Jr.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : 364 - 369
  • [32] Prognostic factors for and prognostic value of mesenteric lymph node involvement in advanced-stage ovarian cancer
    Gouy, S.
    Goetgheluck, J.
    Uzan, C.
    Duclos, J.
    Duvillard, P.
    Morice, P.
    EJSO, 2012, 38 (02): : 170 - 175
  • [33] Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high-grade serous ovarian cancer
    Cardillo, Nicholas
    Devor, Eric
    Calma, Christian
    Pedra Nobre, Silvana
    Gabrilovich, Sofia
    Bender, David P.
    Goodheart, Michael
    Gonzalez-Bosquet, Jesus
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2022, 101 (10) : 1085 - 1092
  • [34] Primary Chemotherapy The Future for the Management of Advanced Ovarian Cancer?
    Ledermann, Jonathan A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 : S17 - S19
  • [35] Risk of Ovarian Cancer Relapse Score A Prognostic Algorithm to Predict Relapse Following Treatment for Advanced Ovarian Cancer
    Rizzuto, Ivana
    Stavraka, Chara
    Chatterjee, Jayanta
    Borley, Jane
    Hopkins, Thomas Glass
    Gabra, Hani
    Ghaem-Maghami, Sadaf
    Huson, Les
    Blagden, Sarah P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (03) : 416 - 422
  • [36] Nomogram for predicting incomplete cytoreduction in advanced ovarian cancer patients
    Shim, Seung-Hyuk
    Lee, Sun Joo
    Kim, Seon-Ok
    Kim, Soo-Nyung
    Kim, Dae-Yeon
    Lee, Jong Jin
    Kim, Jong-Hyeok
    Kim, Yong-Man
    Kim, Young-Tak
    Nam, Joo-Hyun
    GYNECOLOGIC ONCOLOGY, 2015, 136 (01) : 30 - 36
  • [37] Chemokine Ligand 5 to Predict Optimal Cytoreduction in Ovarian Cancer
    Hidayat, Yudi Mulyana
    Munizar
    Harsono, Ali Budi
    Winarno, Gatot Nyarumenteng Adhipurnawan
    Hasanuddin
    Salima, Siti
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2020, 13 : 1201 - 1206
  • [38] New terminology for cytoreduction in advanced ovarian cancer
    Zapardiel, Ignacio
    Morrow, C. Paul
    LANCET ONCOLOGY, 2011, 12 (03) : 214 - 214
  • [39] Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer
    Tanner, Edward J.
    Long, Kara C.
    Zhou, Qin
    Brightwell, Rachel M.
    Gardner, Ginger J.
    Abu-Rustum, Nadeem R.
    Leitao, Mario M., Jr.
    Sonoda, Yukio
    Barakat, Richard R.
    Iasonos, Alexia
    Chi, Dennis S.
    GYNECOLOGIC ONCOLOGY, 2012, 126 (01) : 58 - 63
  • [40] Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes
    Peiretti, Michele
    Bristow, Robert E.
    Zapardiel, Ignacio
    Gerardi, Melissa
    Zanagnolo, Vanna
    Biffi, Roberto
    Landoni, Fabio
    Bocciolone, Luca
    Aletti, Giovanni Damiano
    Maggioni, Angelo
    GYNECOLOGIC ONCOLOGY, 2012, 126 (02) : 220 - 223